# Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

> **NCT04569786** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 232 (actual)

## Conditions studied

- Coronavirus Disease (COVID-19)

## Interventions

- **BIOLOGICAL:** V590
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04569786
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-29
- **Primary completion:** 2021-02-18
- **Final completion:** 2021-02-18
- **Target enrollment:** 232 (ACTUAL)
- **Why stopped:** The study was terminated based on an interim assessment of immunogenicity.
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04569786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04569786, "Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04569786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*